Abstract
Patients aged ≥60 years with treatment-naive Hodgkin lymphoma (HL) have few treatment options and inferior survival due to treatment-related toxicities and comorbidities. This phase 2, nonrandomized, open-label study evaluated brentuximab vedotin (BV) monotherapy (results previously reported), BV plus dacarbazine (DTIC), and BV plus bendamustine. Patients had classical HL and were ineligible for or declined frontline chemotherapy. Twenty-two patients received 1.8 mg/kg BV and 375 mg/m2 DTIC for up to 12 cycles, and 20 more patients received 1.8 mg/kg BV plus 90 or 70 mg/m2 bendamustine for up to 6 cycles (dose reduced due to toxicity). Subsequent BV monotherapy was allowed. Approximately 30 patients were to receive BV plus bendamustine; however, the incidence of serious adverse events (65%) and 2 deaths on study led to discontinuation of bendamustine and cessation of enrollment. Most patients had stage III/IV disease, and approximately half had ≥3 comorbidities or were impaired in ≥1 aspect that significantly interfered with quality of life. For BV plus DTIC, the objective response rate (ORR) was 100% and the complete remission (CR) rate was 62%. To date, the median progressionfree survival (PFS) is 17.9 months. ForBVplusbendamustine, theORRwas 100%and theCRrate was88%. Neither the medianPFSnor overall survival was reached. For elderly patients with HL, BV plus DTIC may be a frontline option based on tolerability and response duration. Despite activity, BV plus bendamustine is not a tolerable regimen in these patients. This trial was registered at www. clinicaltrials.gov as #NCT01716806.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2829-2837 |
| Number of pages | 9 |
| Journal | Blood |
| Volume | 130 |
| Issue number | 26 |
| DOIs | |
| State | Published - Dec 28 2017 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. / Friedberg, Jonathan W.; Forero-Torres, Andres; Bordoni, Rodolfo E.; Cline, Vivian J.M.; Patel-Donnelly, Dipti; Flynn, Patrick J.; Olsen, Gregg; Chen, Robert; Fong, Abraham; Wang, Yinghui; Yasenchak, Christopher A.
In: Blood, Vol. 130, No. 26, 28.12.2017, p. 2829-2837.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
AU - Friedberg, Jonathan W.
AU - Forero-Torres, Andres
AU - Bordoni, Rodolfo E.
AU - Cline, Vivian J.M.
AU - Patel-Donnelly, Dipti
AU - Flynn, Patrick J.
AU - Olsen, Gregg
AU - Chen, Robert
AU - Fong, Abraham
AU - Wang, Yinghui
AU - Yasenchak, Christopher A.
PY - 2017/12/28
Y1 - 2017/12/28
N2 - Patients aged ≥60 years with treatment-naive Hodgkin lymphoma (HL) have few treatment options and inferior survival due to treatment-related toxicities and comorbidities. This phase 2, nonrandomized, open-label study evaluated brentuximab vedotin (BV) monotherapy (results previously reported), BV plus dacarbazine (DTIC), and BV plus bendamustine. Patients had classical HL and were ineligible for or declined frontline chemotherapy. Twenty-two patients received 1.8 mg/kg BV and 375 mg/m2 DTIC for up to 12 cycles, and 20 more patients received 1.8 mg/kg BV plus 90 or 70 mg/m2 bendamustine for up to 6 cycles (dose reduced due to toxicity). Subsequent BV monotherapy was allowed. Approximately 30 patients were to receive BV plus bendamustine; however, the incidence of serious adverse events (65%) and 2 deaths on study led to discontinuation of bendamustine and cessation of enrollment. Most patients had stage III/IV disease, and approximately half had ≥3 comorbidities or were impaired in ≥1 aspect that significantly interfered with quality of life. For BV plus DTIC, the objective response rate (ORR) was 100% and the complete remission (CR) rate was 62%. To date, the median progressionfree survival (PFS) is 17.9 months. ForBVplusbendamustine, theORRwas 100%and theCRrate was88%. Neither the medianPFSnor overall survival was reached. For elderly patients with HL, BV plus DTIC may be a frontline option based on tolerability and response duration. Despite activity, BV plus bendamustine is not a tolerable regimen in these patients. This trial was registered at www. clinicaltrials.gov as #NCT01716806.
AB - Patients aged ≥60 years with treatment-naive Hodgkin lymphoma (HL) have few treatment options and inferior survival due to treatment-related toxicities and comorbidities. This phase 2, nonrandomized, open-label study evaluated brentuximab vedotin (BV) monotherapy (results previously reported), BV plus dacarbazine (DTIC), and BV plus bendamustine. Patients had classical HL and were ineligible for or declined frontline chemotherapy. Twenty-two patients received 1.8 mg/kg BV and 375 mg/m2 DTIC for up to 12 cycles, and 20 more patients received 1.8 mg/kg BV plus 90 or 70 mg/m2 bendamustine for up to 6 cycles (dose reduced due to toxicity). Subsequent BV monotherapy was allowed. Approximately 30 patients were to receive BV plus bendamustine; however, the incidence of serious adverse events (65%) and 2 deaths on study led to discontinuation of bendamustine and cessation of enrollment. Most patients had stage III/IV disease, and approximately half had ≥3 comorbidities or were impaired in ≥1 aspect that significantly interfered with quality of life. For BV plus DTIC, the objective response rate (ORR) was 100% and the complete remission (CR) rate was 62%. To date, the median progressionfree survival (PFS) is 17.9 months. ForBVplusbendamustine, theORRwas 100%and theCRrate was88%. Neither the medianPFSnor overall survival was reached. For elderly patients with HL, BV plus DTIC may be a frontline option based on tolerability and response duration. Despite activity, BV plus bendamustine is not a tolerable regimen in these patients. This trial was registered at www. clinicaltrials.gov as #NCT01716806.
UR - http://www.scopus.com/inward/record.url?scp=85039789885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039789885&partnerID=8YFLogxK
U2 - 10.1182/blood-2017-06-787200
DO - 10.1182/blood-2017-06-787200
M3 - Article
C2 - 29038340
AN - SCOPUS:85039789885
VL - 130
SP - 2829
EP - 2837
JO - Blood
JF - Blood
SN - 0006-4971
IS - 26
ER -